Growing Shareholder Value

Press Releases

Planet abiomed Inc.
Oct 25,2016

Abiomed's Impella Technology Showcased at TCT 2016 With More Than 25 Presentations During Scientific Sessions

DANVERS, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announces that there are more than 25 presentations potentially featuring the Impella® line of heart pumps, scheduled during the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific meeting, being held October 29 — November 2, at the Walter E. Washington Convention Center in Washington, DC.

Abiomed is committed to improving outcomes in Protected PCI and cardiogenic shock through technology and innovation, excellence in education, clinical research, and appropriate and standardized use. The following initiatives are planned for TCT:

  • Abiomed Booth Activities
    Abiomed's booth #2120 will feature daily demonstrations and opportunities for physicians to engage in hands-on simulations of the Impella platform with new simulator updates.  Dr. Thorsten Siess, Abiomed's Chief Technology Officer and the inventor of Impella technology, will discuss new technologies and innovations. Additionally, Abiomed's Mobile Learning Lab at booth #1169, will be open for highly interactive training.

  • New Abiomed Impella Quality (IQ) Assurance Program
    Abiomed will announce the new IQ Assurance Program, an initiative designed to improve outcomes in Protected PCI and cardiogenic shock. One component of the program is Abiomed's IQ database, which includes observational quality assurance data on over 99% of patients treated with Impella devices. This, combined with clinical data collected in the cVAD Registry and on-going FDA post-market studies, is used to develop clinical protocols by highlighting the best practices associated with superior, real world outcomes.

  • Debut of Digital Community
    Abiomed's new digital community is now the largest source of educational resources on pVADs and Impella. Materials available on the community include state of the art training materials, protocols for appropriate use, summaries on the latest clinical publications and studies, case recordings, conference news (including updates from TCT 2016), and video interviews with leading experts.

  • Potential Live Cases Utilizing Impella
    Abiomed anticipates the potential broadcast of several live cases utilizing Impella devices from participating sites in the main arena, coronary theater, and structural heart theater in the Washington Convention Center.  Further details regarding these live cases will be announced the day of the scheduled procedures, as patient status is subject to change. 

  • Investor Breakfast
    Abiomed will host an investor breakfast on Tuesday, November 1, at 6:30 — 8:00 a.m. To request attendance, please email
    Speakers include:
    Michael R. Minogue, CEO, President & Chairman of the Board
    Dr. Seth Bilazarian, Chief Medical Officer
    Dr. Thorsten Siess, Chief Technology Officer

The schedule for Protected PCI and cardiogenic shock-related TCT symposia is included below.  Additional Impella-related presentations and poster sessions are anticipated at TCT.  

New FDA Indications for the Use of Percutaneous Hemodynamic Support: Improving Outcomes in Protected PCI and CGS Presentation Theater Program (Sponsored by the Cardiovascular Research Foundation)
Walter E. Washington Convention Center — Presentation Theater 3

11:30 AM — 12:30 PM
Navin K. Kapur, MD
William L. Lombardi, MD
James M. McCabe, MD

TCT Breakfast Session: Management of Complex PCI Patients: Award Winning Case Presentations Fellows - Breakfast Symposium
Walter E. Washington Convention Center — Room 143A, Street Level

6:30 — 8:00 AM
Michael P. Flaherty, MD
Perwaiz M. Meraj, MD
George W. Vetrovec, MD
Sukhdeep Singh Basra, MD
Nileshkumar Patel, MD
Nishtha Sareen, MD

TCT Symposium: The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP) Co-Sponsored Evening Program (Sponsored by the Cardiovascular Research Foundation)
Marriott Marquis Washington, D.C. — Marquis Ballroom (Salon 5)

6:00 — 8:00 PM
Jeffrey W. Moses, MD
Gregg W. Stone, MD
Ajay J. Kirtane, MD
Emmanouil S. Brilakis, MD
Susheel Kodali, MD
Manish A. Parikh, MD
Simon J. Walsh, MD

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.  For additional information please visit:

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For further information please contact: 

Ingrid Goldberg 
Director, Investor Relations